Serum Instittute
- All
- News
-
Serum Institute Says Working To Develop Monkeypox Vaccine
Serum Institute of India on Tuesday said it is currently working to develop a vaccine for Monkeypox, with positive outcomes expected in a year's time.
-
Serum Institute Buys 50% Stake In Country's Largest Vial Maker Schott Kaisha
Schott Kaisha is a joint venture between specialty glass makers Schott AG from Germany and India's Kaisha, producing the highest number of ampoules and vials in the country at around 2.5 billion units per year.
-
Novavax Applies For Emergency Use Approval Of Its Covid Vaccine In India
US-based vaccine maker Novavax has filed regulatory submissions for emergency use authorization in India. The submissions were made to the Drugs Controller General of India (DCGI) through its partner, Serum Institute of India (SII), which also manufa
-
Serum Institute Writes To Centre Over Drug Regulatory Reforms: Report
Serum Institute of India (SII) has written to Union Health Minister Mansukh Mandaviya suggesting reforms in the existing drug regulatory system, including allowing manufacturing and stockpiling of non-Covid vaccines while undergoing clinical trial.
-
"Please Be Patient": Adar Poonawalla To Nations Waiting For Vaccines
World's biggest vaccine maker Serum Institute of India's Adar Poonawalla this morning urged the nations to "be patient" amid the wait for Covishield, the coronavirus vaccine that the SII has developed in partnership with the Oxford University and British-Swedish pharma firm AstraZeneca.
-
Serum Institute Says Working To Develop Monkeypox Vaccine
Serum Institute of India on Tuesday said it is currently working to develop a vaccine for Monkeypox, with positive outcomes expected in a year's time.
-
Serum Institute Buys 50% Stake In Country's Largest Vial Maker Schott Kaisha
Schott Kaisha is a joint venture between specialty glass makers Schott AG from Germany and India's Kaisha, producing the highest number of ampoules and vials in the country at around 2.5 billion units per year.
-
Novavax Applies For Emergency Use Approval Of Its Covid Vaccine In India
US-based vaccine maker Novavax has filed regulatory submissions for emergency use authorization in India. The submissions were made to the Drugs Controller General of India (DCGI) through its partner, Serum Institute of India (SII), which also manufa
-
Serum Institute Writes To Centre Over Drug Regulatory Reforms: Report
Serum Institute of India (SII) has written to Union Health Minister Mansukh Mandaviya suggesting reforms in the existing drug regulatory system, including allowing manufacturing and stockpiling of non-Covid vaccines while undergoing clinical trial.
-
"Please Be Patient": Adar Poonawalla To Nations Waiting For Vaccines
World's biggest vaccine maker Serum Institute of India's Adar Poonawalla this morning urged the nations to "be patient" amid the wait for Covishield, the coronavirus vaccine that the SII has developed in partnership with the Oxford University and British-Swedish pharma firm AstraZeneca.
